Community Pharmacies and the Economics of Shortages

Community pharmacies often make the same observation during a shortage cycle:
“As soon as a price concession is granted, the medicine suddenly becomes available.”

The implication is that supply has magically returned.
It hasn’t.

What has changed is not availability, but economic viability. To understand why, we need to look far beyond healthcare,back to the Cornish tin mines.

A Lesson from the Cornish Tin Mines

For centuries, Cornwall’s tin mines opened and closed in response to a single variable: the price of tin.

When prices were high, marginal mines reopened. Shafts were pumped dry, workers rehired, and production resumed. When prices fell, those same mines shut again, not because the tin had disappeared, but because extracting it no longer made economic sense.

The tin was always there.
What fluctuated was whether anyone could afford to produce it.

Generic Medicines Behave the Same Way

Market signals shows this pattern repeating with remarkable consistency. Problems rarely begin during periods of volatility. They emerge after long stretches of apparent stability, when prices have been driven down to pennies and the Drug Tariff reimbursement falls below £1 per pack.

This is typically the point at which a product crosses from low-margin to structurally unsustainable.

At sub-£1 reimbursement:

  • There is little or no headroom to absorb input cost changes.

  • Any concession, delay, or write-off immediately crystallises a loss.

  • The economics no longer support holding buffer stock anywhere in the supply chain.

From the outside, the market looks calm. In reality, it is brittle.

The moment any pressure appears, a batch delay, a cost increase, a regulatory intervention - the system has no resilience left to give.

Low-cost generics follow almost exactly the same pattern. When reimbursement prices are driven down to pennies, manufacturers and suppliers don’t suddenly lose the ability to make or hold stock. What they lose is the ability to do so without incurring a loss.

At ultra-low prices:

  • Production may technically continue, but only at minimal volumes.

  • Inventory is deprioritised in favour of higher-margin products.

  • Wholesalers ration stock to manage financial exposure.

  • Pharmacies see “no availability” despite physical stock existing somewhere in the system.

The medicine hasn’t vanished.
It has simply dropped below its economic extraction price.

Why Price Concessions Appear to ‘Fix’ Shortages

When a price concession is finally granted, the market interprets it as a signal:
It is now safe to release stock.

Manufacturers can sell without crystallising losses. Wholesalers can distribute without margin erosion. Stock that was already in warehouses begins to flow.

From the pharmacy’s perspective, availability seems to return overnight.

But this is not recovery. It is delayed release.

Just as with tin mining, higher prices don’t create the resource - they make access to it viable again.

The Dangerous Myth of “Unexpected Shortages”

Calling these events shortages obscures the real issue.

This is not a failure of manufacturing capacity or logistics. It is the foreseeable outcome of pricing signals that fall below sustainable levels.

Markets cannot operate indefinitely at prices that ignore:

  • Fixed manufacturing costs.

  • Regulatory overhead.

  • Working capital constraints.

  • Risk premiums for volatility.

Eventually, supply doesn’t stop - it waits.

When Most of the Portfolio Loses Money

In conversations with major wholesalers and generic manufacturers, a striking figure comes up again and again: at least 70% of their generic portfolios operate at a loss.

That number should stop us in our tracks.

Why do we expect this?

In almost any other industry, a business model where the majority of products are knowingly sold below cost would be considered unsustainable, or irrational. In medicines, we have normalised it.

This is particularly perverse in a sector where quality equals patient safety. Regulatory compliance, pharmacovigilance, manufacturing standards, and supply assurance all carry fixed costs that do not shrink just because the price has been driven into pennies.

Yet the system implicitly assumes that manufacturers, wholesalers, and pharmacies will continue to absorb losses, cross-subsidise indefinitely, and maintain resilience,simply because the product is clinically essential.

That assumption is not just optimistic. It is reckless.

What This Means for Policy and Practice

If we continue to optimise solely for the lowest possible price, we should expect more of these cycles:

  • Long periods of apparent scarcity.

  • Sudden reappearance after concessions.

  • Growing mistrust between pharmacies, wholesalers, and manufacturers.

The Cornish tin mines teach us a simple lesson: resources don’t disappear when prices fall - they become inaccessible.

Generic medicines are no different.

Until pricing frameworks recognise the difference between cheap and viable, we will keep mistaking economic signals for supply failures - and repeating the same mistakes, over and over again.